166 related articles for article (PubMed ID: 33723568)
1. Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study.
Fukui S; Kawaai S; Nakai T; Suda M; Ikeda Y; Nomura A; Tamaki H; Kishimoto M; Ohde S; Okada M
Rheumatology (Oxford); 2021 Dec; 60(12):5697-5704. PubMed ID: 33723568
[TBL] [Abstract][Full Text] [Related]
2. Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study.
Fukui S; Nakai T; Kawaai S; Ikeda Y; Suda M; Nomura A; Tamaki H; Kishimoto M; Ohde S; Okada M
Medicine (Baltimore); 2022 Sep; 101(39):e30932. PubMed ID: 36181016
[TBL] [Abstract][Full Text] [Related]
3. Mizoribine for the treatment of lupus nephritis in children and adolescents.
Tanaka H; Tsugawa K; Tsuruga K; Suzuki K; Nakahata T; Ito E; Waga S
Clin Nephrol; 2004 Dec; 62(6):412-7. PubMed ID: 15630899
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.
Yumura W; Suganuma S; Uchida K; Moriyama T; Otsubo S; Takei T; Naito M; Koike M; Nitta K; Nihei H
Clin Nephrol; 2005 Jul; 64(1):28-34. PubMed ID: 16047642
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study.
Ushigome H; Uchida K; Nishimura K; Akioka K; Fukuda Y; Yuzawa K; Fujisawa M; Sugitani A; Ito SI; Nakatani T; Horimi T; Yoshimura N
Transplant Proc; 2016 Apr; 48(3):794-8. PubMed ID: 27234738
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis.
Ichinose K; Origuchi T; Kawashiri SY; Iwamoto N; Fujikawa K; Aramaki T; Kamachi M; Arima K; Tamai M; Nakamura H; Ida H; Kawakami A; Tsukada T; Ueki Y; Eguchi K
Intern Med; 2010; 49(20):2211-8. PubMed ID: 20962439
[TBL] [Abstract][Full Text] [Related]
8. Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine.
Ito T; Mochizuki K; Oka T; Hanada K; Tanabe K
Int Urol Nephrol; 2015 Jan; 47(1):131-5. PubMed ID: 25298141
[TBL] [Abstract][Full Text] [Related]
9. Assessment of factors associated with mizoribine responsiveness in children with steroid-dependent nephrotic syndrome.
Kondoh T; Ikezumi Y; Yokoi K; Nakajima Y; Matsumoto Y; Kaneko M; Hasegawa H; Yamada T; Kumagai N; Ito T; Yoshikawa T
Clin Exp Nephrol; 2019 Sep; 23(9):1154-1160. PubMed ID: 31187341
[TBL] [Abstract][Full Text] [Related]
10. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.
Tanaka H; Tsugawa K; Suzuki K; Nakahata T; Ito E
Pediatr Nephrol; 2006 Jul; 21(7):962-6. PubMed ID: 16773408
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis.
Rokutanda R; Kishimoto M; Ohde S; Shimizu H; Nomura A; Suyama Y; Ohara Y; Yamaguchi K; Okada M
Rheumatol Int; 2014 Jan; 34(1):59-62. PubMed ID: 23283538
[TBL] [Abstract][Full Text] [Related]
12. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis.
Tanaka H; Tsugawa K; Nakahata T; Kudo M; Suzuki K; Ito E
Clin Nephrol; 2005 Jun; 63(6):417-22. PubMed ID: 15960142
[TBL] [Abstract][Full Text] [Related]
13. A case report of steroid-resistant antineutrophil cytoplasmic antibody-related vasculitis successfully treated by mizoribine in a hemodialysis patient.
Tokunaga M; Tamura M; Kabashima N; Serino R; Shibata T; Matsumoto M; Miyamoto T; Miyazaki M; Furuno Y; Fujimatsu S; Muta T; Takeuchi M; Abe H; Okazaki M; Otsuji Y
Ther Apher Dial; 2009 Feb; 13(1):77-9. PubMed ID: 19379174
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
15. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Liu Y; Zeng Q; Zhu L; Gao J; Wang Z; Wang Z; Yang F; Wang K; Chen D; Xia C; Zhang S; Wang Y; Shen D; Yu G; Li ZG
Rheumatology (Oxford); 2020 Aug; 59(8):2115-2123. PubMed ID: 32097488
[TBL] [Abstract][Full Text] [Related]
16. Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.
Saito T; Iwano M; Matsumoto K; Mitarai T; Yokoyama H; Yorioka N; Nishi S; Yoshimura A; Sato H; Ogahara S; Sasatomi Y; Kataoka Y; Ueda S; Koyama A; Maruyama S; Nangaku M; Imai E; Matsuo S; Tomino Y;
Clin Exp Nephrol; 2017 Dec; 21(6):961-970. PubMed ID: 27783276
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease.
Phaopraphat K; Ngamjanyaporn P; Narongroeknawin P; Kasitanon N; Katchamart W
Int J Rheum Dis; 2020 Nov; 23(11):1468-1473. PubMed ID: 32808722
[TBL] [Abstract][Full Text] [Related]
18. Usefulness and safety of high-dose mizoribine on ABO-incompatible living related kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy: 3-year results.
Yoshimura N; Ushigome H; Nobori S; Suzuki T; Sakai K; Koshino K; Nakamura T; Nakao T; Harada S; Ito T
Transplant Proc; 2014; 46(2):391-4. PubMed ID: 24655971
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Mizoribine Combined With Tacrolimus in Living Donor Kidney Transplant Recipients: 3-Year Results by a Chinese Single Center Study.
Shi Y; Liu H; Chen XG; Shen ZY
Transplant Proc; 2019 Jun; 51(5):1337-1342. PubMed ID: 31155174
[TBL] [Abstract][Full Text] [Related]
20. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
